undamentalytics Newsletter
Sign in

Lexicon Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Lexicon Pharmaceuticals, Inc.'s operations generated −$67.9m of cash; it spent $0 on capital projects, leaving free cash flow of −$67.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−89−82−88−94−91−76185−176−185−149114−143−87−89−162−179−68−65
Depreciation and amortisation655432123443001110
Stock-based pay556677779121413111214131313
Capital spending011020100000110100
Free cash flow−89−84−89−95−93−76184−176−186−149114−143−88−90−162−180−68−65
Free cash flow after stock pay−95−89−95−101−100−83177−183−195−160100−156−99−102−177−193−80−78
Share buybacks0000110121113112——
Shares issued551811613812020481070379413900—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CUE vs LXRXLXRX vs STROLXRX vs ZYME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lexicon Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lexicon Pharmaceuticals, Inc.